drugset / Trial / NCT01012089
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
Completed
6 enrolled
University of Oklahoma
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · collab
NaSingle-groupOpen-labelOther
Summary
The purpose of this study is to: 1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD). 2. Determine urine, HD and PD clearance of daptomycin.
Timeline
- Start
- 2009-11
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daptomycin | Other / unclassified | 5 mg/kg | Intravenous |